Ranolazine

Contraindicated

Ranolazine Relugolix Orgovyx Explained Reduced ranolazine exposure, increased relugolix exposure and an increased risk of QT interval prolongation Details Ranolazine Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of potential life-threatening toxicity Details Ranolazine Bexarotene Targretin Reduced ranolazine exposure Details Ranolazine Bexarotene Topical Targretin Reduced ranolazine exposure Details Ranolazine Brigatinib Alunbrig Altered ranolazine exposure and an increased CYP3A4 substrate exposure Details Ranolazine Brivaracetam Briviact Reduced ranolazine exposure Details Ranolazine Brivaracetam Injection Briviact Reduced ranolazine exposure Details Ranolazine Darolutamide Nubeqa Reduced ranolazine exposure Details Ranolazine Dexamethasone Injection Decadron Reduced ranolazine exposure Details Ranolazine Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced ranolazine exposure Details Ranolazine Enasidenib Idhifa Increased or reduced ranolazine exposure Details Ranolazine Encorafenib Braftovi Increased risk of QT interval prolongation; reduced ranolazine exposure Details Ranolazine Ketoconazole Topical Extina® Foam An increase in ranolazine exposure and an increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Ranolazine Mitapivat Aqvesme Reduced ranolazine exposure and increased mitapivat exposure Details Ranolazine Nafcillin Injection Unipen® Injection Reduced ranolazine exposure Details Ranolazine Nevirapine Viramune Reduced ranolazine exposure Details

Major

Ranolazine Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine exposure Details Ranolazine Abametapir Explained Increased exposure of CYP3A4 substrate Details Ranolazine Clindamycin ANTIROBE Explained Increased exposure of CYP3A4 substrate Details Ranolazine Amitriptyline Elavil Explained Increased tricyclic antidepressant exposure Details Ranolazine Sertraline Explained An increased risk of QT interval prolongation Details Ranolazine Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Ranolazine Trospium / Xanomeline Cobenfy Explained Increased CYP2D6 substrates exposure Details Ranolazine Simvastatin Flolipid Explained Increased simvastatin exposure and increased risk of rhabdomyolysis Details Ranolazine Abemaciclib Verzenio Explained Increased exposure of CYP3A4 substrate Details Ranolazine Abrocitinib Cibinqo Explained Increased ranolazine exposure and an increased risk of ranolazine-related adverse effects Details Ranolazine Acalabrutinib Calquence Increased exposure of CYP3A4 substrate Details Ranolazine Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Ranolazine Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Ranolazine Aripiprazole Injection Abilify Increased ARIPiprazole or ARIPiprazole lauroxil (a prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolonga... Details Ranolazine Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Ranolazine Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Ranolazine Atogepant Qulipta Increased exposure of CYP3A4 substrate Details Ranolazine Avapritinib Ayvakit Increased exposure of CYP3A4 substrate Details Ranolazine Azithromycin AzaSite An increased ranolazine exposure and an increased risk of QT interval prolongation Details Ranolazine Betrixaban Bevyxxa® Increased betrixaban exposure and increased risk of bleeding Details Ranolazine Atorvastatin Atorvaliq Increased ranolazine exposure, an increased atorvastatin exposure and increased risk of myopathy Details Ranolazine Afatinib Gilotrif Increased exposure of afatinib Details Ranolazine Alfuzosin UroXatral An increased risk of QT interval prolongation Details Ranolazine Alogliptin Nesina Increased ranolazine exposure and an increased risk of ranolazine-related adverse effects Details